Financials data is unavailable for this security.
View more
Year on year Ajanta Pharma Ltd grew revenues 12.45% from 37.43bn to 42.09bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 38.81% net income growth from 5.88bn to 8.16bn.
| Gross margin | 75.77% |
|---|---|
| Net profit margin | 19.48% |
| Operating margin | 25.17% |
| Return on assets | 18.97% |
|---|---|
| Return on equity | 24.45% |
| Return on investment | 23.29% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Ajanta Pharma Ltd fell by 2.01bn. However, the company earned 7.85bn from its operations for a Cash Flow Margin of 18.65%. In addition the company generated 653.90m cash from investing, though they paid out 10.51bn more in financing than they received.
| Cash flow per share | 80.43 |
|---|---|
| Price/Cash flow per share | 36.36 |
| Book value per share | 294.36 |
|---|---|
| Tangible book value per share | 293.30 |
More ▼
Balance sheet in INRView more
| Current ratio | 3.06 |
|---|---|
| Quick ratio | 2.13 |
| Total debt/total equity | 0.0089 |
|---|---|
| Total debt/total capital | 0.0088 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 42.86% and 41.14%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.57% |
|---|---|
| Div growth rate (5 year) | 10.76% |
| Payout ratio (TTM) | 39.97% |
| EPS growth(5 years) | 17.18 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 33.57 |
More ▼
